FY2025 EPS Estimates for TSHA Lifted by Cantor Fitzgerald

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) – Equities researchers at Cantor Fitzgerald increased their FY2025 EPS estimates for Taysha Gene Therapies in a note issued to investors on Monday, May 19th. Cantor Fitzgerald analyst K. Kluska now expects that the company will post earnings of ($0.36) per share for the year, up from their prior forecast of ($0.38). Cantor Fitzgerald has a “Overweight” rating and a $7.00 price objective on the stock. The consensus estimate for Taysha Gene Therapies’ current full-year earnings is ($0.35) per share.

Taysha Gene Therapies (NASDAQ:TSHA) last posted its earnings results on Thursday, May 15th. The company reported ($0.08) EPS for the quarter, hitting analysts’ consensus estimates of ($0.08). Taysha Gene Therapies had a negative net margin of 229.67% and a negative return on equity of 106.36%. The business had revenue of $2.30 million for the quarter, compared to analysts’ expectations of $1.48 million. During the same period in the previous year, the company posted ($0.10) earnings per share.

TSHA has been the topic of a number of other reports. JMP Securities reissued a “market outperform” rating and set a $5.00 target price on shares of Taysha Gene Therapies in a research report on Monday, April 28th. Needham & Company LLC restated a “buy” rating and issued a $6.00 price target on shares of Taysha Gene Therapies in a research note on Thursday, April 10th. Chardan Capital restated a “buy” rating and issued a $7.00 price target on shares of Taysha Gene Therapies in a research note on Wednesday, February 26th. Finally, Canaccord Genuity Group lifted their price target on shares of Taysha Gene Therapies from $8.00 to $9.00 and gave the stock a “buy” rating in a research note on Friday, May 16th. Seven investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $6.57.

Taysha Gene Therapies Trading Down 1.4%

NASDAQ TSHA opened at $2.89 on Wednesday. The company’s fifty day simple moving average is $1.79 and its 200-day simple moving average is $1.85. Taysha Gene Therapies has a 52 week low of $1.05 and a 52 week high of $4.32. The company has a current ratio of 5.51, a quick ratio of 5.51 and a debt-to-equity ratio of 0.48. The stock has a market cap of $592.61 million, a P/E ratio of 4.59 and a beta of 0.90.

Institutional Trading of Taysha Gene Therapies

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Ground Swell Capital LLC bought a new stake in shares of Taysha Gene Therapies in the fourth quarter worth $25,000. Cibc World Markets Corp bought a new stake in Taysha Gene Therapies during the fourth quarter valued at $28,000. E Fund Management Co. Ltd. bought a new stake in Taysha Gene Therapies during the fourth quarter valued at $31,000. Hsbc Holdings PLC increased its stake in Taysha Gene Therapies by 65.6% during the fourth quarter. Hsbc Holdings PLC now owns 20,391 shares of the company’s stock valued at $36,000 after purchasing an additional 8,076 shares during the last quarter. Finally, AXQ Capital LP bought a new stake in Taysha Gene Therapies during the fourth quarter valued at $39,000. Institutional investors own 77.70% of the company’s stock.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.